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Selective impairment of gene expression and assembly of
nephrin in human diabetic nephropathy.
Background. Recent disclosure of podocyte proteins has un-
raveled previously rather mysterious mechanisms that govern
glomerular perm-selectivity in health and disease. Here we ad-
dressed the role of nephrin, CD2-associated protein (CD2AP),
and podocin together with the integrity of the slit diaphragm
in the pathogenesis of proteinuria of patients with diabetes and
nephropathy.
Methods. Nephrin mRNA and protein expression were eval-
uated in parallel in adult diabetic patients by in situ hybridiza-
tion and immunohistochemistry. For comparison, nondiabetic
patients with minimal change nephrosis and normal control
patients were evaluated. CD2AP and podocin expression by
immunohistochemistry was also assessed. The filtration slit
was analyzed by morphometry and transmission electron mi-
croscopy.
Results. Extracellular nephrin mRNA and protein were
markedly reduced in diabetic patients. No changes were found
in patients with minimal change versus controls. CD2AP and
podocin were comparable in all subjects. Ultrastructural analy-
sis showed in diabetic patients a remarkable reduction in the
percentage of electron dense slit diaphragms, despite a fre-
quency of the filtration slits comparable to control patients.
Conclusion. Down-regulation of nephrin and loss of the
electron dense structure of slit diaphragm indicate a novel
mechanism accounting for proteinuria in diabetic nephropathy.
To the extent that glomerular protein trafficking contributes
to renal disease progression, our findings may have clinical
relevance. Reduction of nephrin in the context of normal ex-
pression of CD2AP and podocin can be taken reasonably as a
specific marker of renal disease in diabetes. Therapies targeted
at correcting podocyte nephrin might be of value for diabetic
medicine.
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The nephropathy associated with diabetes is the lead-
ing cause of end-stage renal disease (ESRD) worldwide
[1, 2]. In North America, 40% of patients adhering to
dialysis transplantation programs in 1998 were diabetic.
Related treatment costs were estimated at $51,000 per
year (i.e., about $12,000 more than the costs for nondia-
betics).
Diabetic nephropathy, defined as urinary protein ex-
cretion rate >0.5 g/24 hours (clinical proteinuria), man-
ifests within 15 to 20 years after the onset of disease in
20% to 40% of patients. Ultrafiltered proteins concur via
intrinsic renal toxicity [3] to accelerate multifactorial pro-
cesses responsible for progressive loss of glomerular fil-
tration rate (GFR), on average by 10 to 12 mL per minute
per year in untreated diabetics [3]. Restoring the perms-
elective function of the kidney barrier to proteins limits
GFR decline that may even stabilize if proteinuria is re-
duced below 0.5 g/24 hours [4, 5]. While now 0.5 g/24
hours or less is an acknowledged target of renoprotective
intervention in other conditions, such a goal is rather diffi-
cult to achieve in diabetes [6]. The main reason lies in the
relatively poor knowledge of mechanisms sustaining the
glomerular defect. Major highlights have been offered by
recent discoveries on podocytes and slit diaphragm com-
ponent structures, namely nephrin and other functionally
relevant molecules of the barrier.
Nephrin is a transmembrane protein of the im-
munoglobulin superfamily, predominantly expressed by
podocytes [7]. Another protein, CD2AP, acts as an
adapter molecule to bind nephrin carboxy terminal do-
main, which serves to link the slit diaphragm to the
podocyte cytoskeleton [8]. Mutations of the nephrin
gene in severe congenital nephrotic syndrome of Finnish
type [9, 10] resulted in massive proteinuria in utero and
nephrotic syndrome at birth. Animal studies found that
decreased nephrin expression was consistently associ-
ated with altered glomerular permeability to proteins [11,
12]. In severe passive Heymann nephritis, less glomeru-
lar expression of nephrin paralleled the development of
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Table 1. Clinical parameters at the time of biopsy
Age Gender U-Prot S-Creat SBP DBP
Diagnosis years M/F g/day mg/dL mm Hg mm Hg
Minimal change nephrosis 53 ± 10 4/2 5.2 ± 1.4 1.8 ± 0.5 118 ± 6 77 ± 4
Diabetic nephropathy 60 ± 4 10/5 4.1 ± 1 1.6 ± 0.2 143 ± 7 81 ± 3
Abbreviations are: U-Prot, urinary protein excretion; S-Creat, serum creatinine concentration; SBP, systolic blood pressure; DBP, diastolic blood pressure.
proteinuria and injury [11]. Others found similar results
in experimental diabetes and renal mass ablation [13,
14]. Studies on nephrin expression in acquired human
nephroses led to controversial results due to the lack
of simultaneous assessment of nephrin mRNA and pro-
tein expression [15–18]. Two very recent studies, sepa-
rately exploring the expression of nephrin mRNA or the
relative protein product, found a reduction in diabetic
patients [19, 20]. Here, we evaluated nephrin mRNA
and protein expression in a more systematic way, to-
gether with other podocyte proteins, including CD2AP
and podocin, in patients with diabetic nephropathy in
comparison with nondiabetic proteinuric patients with
minimal change and normal control patients. We further
investigated the filtration slit architecture by transmis-
sion electron microscopy, with special attention of the
electron dense structure of slit diaphragms, along with
the morphometric assessment of the slit pore frequency
and width.
METHODS
Patients
This observational study considered all consecutive pa-
tients admitted for diagnostic biopsy to the Renal Unit of
the “Ospedali Riuniti” of Bergamo since the study start
(January 2001) until November 2002, at closure of the
database.
The predefined inclusion criteria for potentially el-
igible subjects were: age ≥16 years; admission to the
Renal Unit in the same period; kidney biopsy for
clinical reasons; no previous steroid or immunosuppres-
sive therapy for at least six months; no previous treat-
ment with (or withdrawal since at least two months
of) angiotensin-converting enzyme (ACE) inhibitors, an-
giotensin II receptor antagonists, statins, nonsteroidal
anti-inflammatory drugs, and other treatments that could
potentially affect urinary protein excretion, nephrin ex-
pression, and any parameter that, in the Investigators’
judgment could confound the findings; serum creatinine
<4 mg/dL (in order to exclude aspecific changes that
might reflect progressive structural damage by mech-
anisms sustained by intracapillary hypertension and
protein traffic); no evidence of renovascular disease, ob-
structive uropathy, systemic disease, and other possibly
confounding conditions; HbA1c <8%; and informed con-
sent (including that of the parents for the 16-year-old
patient).
Specific inclusion criteria for cases were: proteinuria
>0.5 g/24 hours for at least six months; and histo-
logic diagnosis of diabetic glomerulopathy without other
concomitant glomerular disease. Inclusion criteria for
proteinuric control patients were: proteinuria >0.5 g/
24 hours for at least six months; and histologic diagno-
sis of minimal change disease without other concomitant
glomerular disease. Inclusion criteria for nonproteinuric
control patients were: proteinuria <0.5 g/24 hours; no
clinical or histologic evidence of glomerular disease; and
nephrectomy for kidney adenocarcinoma.
Table 1 summarizes clinical features. Twenty-four–
hour urinary proteins and serum creatinine were
measured using an autoanalyzer (CX5; Beckman Instru-
ments, Inc., Fullerton, CA, USA).
Reagents
Goat polyclonal antibody raised against a peptide map-
ping near the amino terminus of nephrin of human ori-
gin and rabbit polyclonal antibody to a recombinant pro-
tein corresponding to amino acids 350–639 mapping at
the carboxy terminus of human CD2AP was from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit
polyclonal anti-podocin antibody were obtained as pre-
viously described [21]. Rabbit polyclonal antibody di-
rected against the intracellular domain of mouse nephrin
[22] was kindly provided by Dr. L.B. Holzman. A 346-bp
fragment of mouse nephrin cDNA (positions 1155–1501)
coding for a portion of the extracellular domain was con-
structed by polymerase chain reaction (PCR) amplifica-
tion of the 2400-bp fragment of mouse nephrin cDNA [11]
using specific primers. The PCR product was gel-purified,
digested, and subcloned into pBluescript SK (Stratagene,
Florence, Italy).
In situ hybridization
Mouse nephrin antisense and sense riboprobes were la-
beled by in vitro transcription using digoxigenin-labeled
uridine triphosphate (Roche, Milan, Italy) according to
the manufacturer’s protocol. The sequence of nephrin
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riboprobe showed 82% homology to the human se-
quence. Hybridization was performed as previously de-
scribed [11] on 3 lm-thick sections of Dubosq-Brazil
fixed, paraffin-embedded renal tissue. Sets of biopsies
comprising samples from each patient group were pro-
cessed simultaneously. Glomeruli (N =7) for each sample
were analyzed. Negative control included hybridization
with sense probe. Evaluation was done without knowl-
edge of the study groups.
Immunohistochemical analysis
Nephrin, CD2AP, and podocin expression was de-
tected by immunoperoxidase analysis. Dubosq-Brazil
fixed, paraffin-embedded kidney sections (3-lm) were
deparaffinized, rehydrated, and incubated for 30 min-
utes with 0.3% H2O2 in methanol to quench endogenous
peroxidase. Tissues were treated with proteinase-K (20
lg/mL, Sigma-Aldrich, Milan, Italy) for 10 minutes at
37◦C, followed by microwave (twice for 5 minutes in cit-
rate buffer 10 mmol/L, pH 6 at operating frequency of
2450 MHz and 600-W power output) and citrate buffer
(15 minutes) incubations to increase the reactivity of anti-
body to antigen. Antibodies against extra- and intracellu-
lar nephrin domains, CD2AP and podocin, were diluted
1:100, 1:300, 1:100, and 1:1000, respectively. Samples from
each group were processed simultaneously. Negative con-
trols were obtained by omitting the primary antibody on
adjacent sections. Seven glomeruli on average in each
sample were analyzed by an investigator who was un-
aware of biopsy groups. Signal intensity was graded on
a scale of 0 to 3 (0, no staining; 1, weak; 2, moderate; 3,
strong intensity).
Electron microscopy
Biopsy specimens were fixed in 2.5% glutaralde-
hyde in 0.1 mol/L cacodylate buffer, pH 7.4, and
postfixed with 1% tannic acid, 1% glutaraldehyde in
0.1 mol/L phosphate buffer, pH 7.4 [23]. Tannic acid
contributes to increase the contrast and definition of
the isoporous substructure of the slit diaphragm [23].
Kidney fragments were then processed, and ultrastruc-
tural evaluations were performed by transmission elec-
tron microscopy (Morgagni 268D; Philips, Brno, Czech
Republic) [24].
Morphometric analysis
The filtration slit was analyzed by morphometry and
transmission electron microscopy in four patients per
group. An average of 45 (35–71) images per patient was
digitized (final magnification × 56,000) and processed
with the image-processing software (NIH Image version
1.6). A total number of 1141 slits was analyzed. Slit
frequency was evaluated as number of slits per lm of
glomerular basement membrane (GBM) length. GBM
length and slit diaphragm width (SDW) were calculated
using computer-assisted morphometric unit. GBM pro-
file and SDW were manually outlined using a line auto-
matically measured in screen pixels. Exact enlargement
was calculated using digitized images of a calibration grid
(Ernest F. Fullam, Inc., Latham, NY, USA). SDW was
calculated, as previously described [25], as the harmonic
mean (in nanometers) of the distance between cell mem-
brane of two adjacent foot processes. The percentage of
measured slit diaphragms with a filamentous structure
was also determined.
Statistical analysis
Results are reported as mean ± SE. Differences be-
tween groups were analyzed by Kruskal-Wallis test.
Linear regression analysis was performed between im-
munohistochemistry scores for nephrin and degree of
proteinuria. A P value <0.05 was considered significant.
RESULTS
Patients
The study included 15 cases with diabetes (type 1: N =
1; type 2: N = 14) and biopsy-proven diabetic glomeru-
lopathy, six proteinuric controls with biopsy-proven
minimal change disease, and five nonproteinuric con-
trols undergoing nephrectomy for kidney adenocarci-
noma without histologic evidence of glomerular disease.
Hypertension was controlled by drugs such as diuretics,
beta-blockers, and vasodilators that did not directly inter-
fere with glomerular barrier function, proteinuria, and,
conceivably, nephrin expression. Metabolic control of di-
abetes was reasonably good (HbA1c <8%). Proteinuria
was comparable in cases and proteinuric control patients
(Table 1).
In situ hybridization for nephrin mRNA
Nephrin expression, typically localized at the periph-
eral capillary loops of the tuft, was absent or markedly
reduced in glomeruli from diabetic patients (Fig. 1A)
in respect to control patients (Fig. 1C and E). By con-
trast, nephrin mRNA staining was comparable in patients
with minimal change nephrosis (Fig. 1B) and control pa-
tients. In all groups, a mild staining was only occasion-
ally observed in parietal epithelial cells and tubuli, as we
observed in severe experimental nephrosis [11]. No back-
ground signal was observed with nephrin sense riboprobe
(Fig. 1D).
Immunoperoxidase staining for nephrin
Results of the immunolocalization of the extracellular
portion of nephrin were consistent with those found for
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Fig. 1. Representative pictures of nephrin mRNA expression by in situ
hybridization in patients with diabetes (A) or minimal change nephrosis
(B), and in control kidney (C and E). No specific signal was obtained
with the sense nephrin probe (control kidney) (D). Arrows indicate
podocyte nephrin expression. Original magnification, ×250 (A-D), and
×1000 (E).
nephrin mRNA. The staining was significantly reduced
or even absent in some glomeruli from patients with dia-
betes (score: 0.7 ± 0.1, P < 0.05) (Fig. 2A) compared to
control patients (3 ± 0) (Fig. 2C). In patients with minimal
change nephrosis the score was fairly comparable to con-
trol patients (2.7 ± 0.2) (Fig. 2B). The staining intensity
was variable along capillary walls. Staining was absent
in control sections upon omission of primary antibody
(Fig. 2D).
A different trend was observed using a specific anti-
body for nephrin intracellular domain, which revealed
comparable capillary wall staining in patients with di-
abetes, minimal change nephrosis, and control patients
(Fig. 3). The pattern was epithelial with linear distribu-
tion along the peripheral loops. Abnormal staining was
found in extensively sclerotic areas, which did not stain.
No signal was observed in negative control experiments
(Fig. 3D).
Immunoperoxidase for CD2AP and podocin
A prominent glomerular localization with a linear dot-
ted line of reactivity, giving a preferentially epithelial-
like staining, was observed for both CD2AP and podocin.
No differences were seen between patients with diabetes
Fig. 2. Representative photomicrographs of nephrin extracellular do-
main by the immunoperoxidase method in patients with diabetes (A)
or minimal change nephrosis (B), and in control kidney (C). No spe-
cific signal was obtained omitting the primary antibody (D). Original
magnification, ×250.
Fig. 3. Representative photomicrographs of nephrin intracellular do-
main by the immunoperoxidase method in patients with diabetes (A)
or minimal change nephrosis (B), and in control kidney (C). No spe-
cific signal was obtained omitting the primary antibody (D). Original
magnification, ×250.
(Fig. 4A and E), minimal change nephrosis (Fig. 4B and
F), and control patients (Fig. 4C and G), all maintain-
ing strong positivity along capillary loops. Sclerotic areas
were negative. No signal was observed omitting the pri-
mary antibodies (Fig. 4D and H). The appreciable differ-
ences between the extracellular portion of nephrin and
CD2AP or podocin staining in diabetic patients indicate
that changes in nephrin protein were selective, rather
than part of a generalized phenomenon.
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Fig. 4. Immunoperoxidase staining for CD2AP and podocin in patients with diabetes (A and E) or minimal change nephrosis (B and F), and in
control kidney (C and G). No signal was obtained omitting the primary antibody (D and H). Original magnification, ×250.
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Fig. 5. Representative transmission electron micrographs of the ultra-
structure capillary wall in patients with diabetes (A) and in control
kidneys (B). (C) An enlarged detail of (B) representing the distance
between two adjacent foot processes used to quantify the slit diaphragm
width is shown. Arrows indicate electron dense diaphragms in the fil-
tration slits. Original magnification, ×36,000.
Electron microscopy studies
We investigated the filtration slit architecture by trans-
mission electron microscopy. In diabetes, the frequency
of filtration slits did not change in comparison with con-
trol patients (1.9 ± 0.15 vs. 1.97 ± 0.08 slits/lm GBM).
In patients with minimal change disease, the frequency of
filtration slits was significantly reduced to 1.09 ± 0.06 slits/
lm GBM in association with the effacement of foot pro-
cesses (P < 0.05). Tannic acid fixation increased the
definition of the electron dense slit diaphragms. The per-
centage of slit diaphragms displaying filamentous image
was significantly reduced in diabetic patients (24% ± 6%,
P < 0.05) in respect to minimal change and control pa-
tients, averaging 50% ± 5% and 63% ± 6%, respectively.
The latter percentages compare reasonably well in few
other available studies [9, 26, 27]. Slit pore width was com-
parable in diabetes (43.95 ± 1.2 nm) or minimal change
(42.2 ± 2.1 nm) and control patients (38.56 ± 2.5 nm).
Figure 5 shows representative pictures of the capillary
wall ultrastructure.
DISCUSSION
Diabetics with nephropathy enrolled in the present
study had remarkably less renal expression of extracel-
lular nephrin than control patients. Changes in nephrin
gene and protein were associated with podocyte ul-
trastructural abnormalities (i.e, reduced percentage of
electron dense diaphragms taken as an index of intact fil-
tration machinery), and loss of filamentous images within
slit diaphragms—reported here for the first time in hu-
man diabetes. Patients with minimal change nephrosis
had no abnormalities in nephrin mRNA and protein
expression or loss of electron dense diaphragms within
the intimate structure of filtration slits, despite extensive
effacement. Differences between diabetic patients and
control patients were clear-cut, achieving statistical sig-
nificance regardless of small sample size. Low expres-
sion of nephrin has been recently observed in diabetic
patients. However, lack of comparison with proteinuric
nondiabetics, and of assessment of other slit diaphragm
molecules prevented conclusions to be drawn on the
specificity and significance of these observations [19, 20].
Findings of reduced nephrin mRNA and protein expres-
sion in human diabetes in the present study are consistent
with reported abnormalities in diabetic rats shown in the
long term [28, 29]. Collectively, our data would indicate
that the slit diaphragm change resulting from selective
reduction in extracellular nephrin may contribute to the
glomerular permeability defect of diabetes. It is conceiv-
able that the nephrin loss would eventually lead to per-
turbed function of interacting slit diaphragm molecules,
resulting in further increases in proteinuria. Alterna-
tively, decreased nephrin could be a consequence of in-
creased protein ultrafiltration, which, however, appears
difficult to reconcile with preserved nephrin in nondia-
betics at comparable levels of proteinuria. Of additional
interest here is the finding of unaltered nephrin levels in
minimal change disease, which could be interpreted to
suggest that the preservation of nephrin may specifically
play a role in preventing this disease from progressing,
in contrast to other forms of glomerular disease, possibly
by maintenance of nephrin-dependent signaling in the
podocyte.
Discovery in the last few years of slit diaphragm pro-
teins uniquely expressed by podocytes has contributed
enormously to the current understanding of the tridimen-
sional structure of the filtration barrier. In such context,
animal models of targeted disruption of single protein or
functional inactivation of a specific domain were instru-
mental. Thus, mice homozygous for inactivated nephrin
gene develop massive proteinuria and die at birth. Null
mice exhibited foot process effacement and no slit di-
aphragms [30]. Alterations in the slit diaphragm organi-
zation can be also induced by infusion of a monoclonal
antibody, recently found to recognize the extracellular
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domain of nephrin [31] and to cause massive proteinuria
[32].
Why should nephrin extracellular domain expression
be impaired in diabetes? The reduction at protein level
underlying the slit diaphragm abnormality reflects re-
duced mRNA, here assessed using a specific probe for
a portion of the extracellular domain. The fact that in-
tracellular nephrin is normally expressed would suggest
a mechanism of alternative splicing of nephrin gene in
diabetes. Nephrin-specific mRNA is spliced in the hu-
man kidney glomeruli with a variant called nephrin a 1
lacking exon 24 coding for the transmembrane domain
[33]. This alternative splicing cannot explain our present
findings. It is possible that in patients with diabetes addi-
tional splicing sites might exist, leading to the formation
of nephrin molecules lacking the extracellular domain.
Theoretically, an additional explanation for our findings
could be the presence of an additional initiation site in the
promoter of nephrin gene in diabetes. That this could oc-
cur is supported by studies that found the existence of dif-
ferent regulatory elements in the nephrin gene promoter
responsible for the presence of different isoforms [34].
Moreover, a recent observation in cultured glomerular
epithelial cells showed changes in cytoskeleton distribu-
tion and cleavage, and shedding of extracellular nephrin
upon angiotensin II challenge [20]. Glycemia-dependent
modifications contributing to abnormal processing or or-
ganization of nephrin were also reported, as documented
by the reduction of nephrin expression on the surface
of cultured podocytes induced by glycated albumin [20].
It is therefore possible that the renin-angiotensin system
activation, together with the abnormal protein glycosyla-
tion in diabetes, modifies the slit diaphragm structure by
impairing the capacity of podocyte proteins to organize
precise tridimensional filtration networks and nephrin at-
tachment sites, which would underlie nephrin depletion.
Defective expression of slit diaphragm–specific
molecules, including CD2AP [8] and podocin [35], which
may serve as anchors for nephrin to the cytoskeleton,
could be conceivably responsible for nephrin reduction.
Lack of CD2AP prevents nephrin binding and the for-
mation of interdigitating processes and slit diaphragms
in vivo [36]. However, preserved CD2AP and podocin
in glomeruli makes the contribution of these molecules
to impaired permselectivity in diabetes unlikely.
CONCLUSION
The expression of the extracellular domain of nephrin
in the podocyte is markedly reduced in human diabetics
with proteinuria, but not in minimal change nephrosis.
Excess ultrafiltration of proteins per se does not explain
altered nephrin in diabetes. Abnormalities were con-
fined to nephrin to the extent that CD2AP and podocin,
nephrin partners contributing to slit diaphragm integrity,
were comparable to control. Alterations of the filtration
slit architecture can be a mechanism of proteinuria in di-
abetes. Nephrin may represent the therapeutic target of
treatments aimed at preventing proteinuria, in the hope
of extinguishing renal disease and possibly limiting car-
diovascular complications of diabetes.
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